Clinical Trial

Testing Treatment for Prostate Cancer

Study Description

Palbociclib in Patients With Metastatic Castration-Resistant Prostate Cancer

The purpose of this study is to find out what effects a new drug, palbociclib, has on prostate cancer and will look at the side effects of treatment with palbociclib. The researchers doing this study are also interested in looking for markers that may help predict which patients are most likely to be helped by palbociclib and to see how the cancer cells respond to palbociclib.

Location

Locations Selected Location

Methods

Pharmaceutical medication involved Pharmaceutical medication involved
Recruiting patients only Recruiting patients only

Drug - Palbociclib

125 mg orally on days 1-21 each 28 day cycle

Additional Information

Official Study Title

A Phase II Study of Palbociclib, A CDK4/6 Inhibitor, in Patients With Metastatic Castration-Resistant Prostate Cancer

Clinical Trial ID

NCT02905318

ParticipAid ID

Pe97Db